J&J Joins Immune Reset Race, Paying $785M to Partner on Sail Bio Cell Therapy
Johnson & Johnson also gains an exclusive option to acquire Sail Biosciences for $2.85 billion….
J&J Joins Immune Reset Race, Paying $785M to Partner on Sail Bio Cell Therapy
Johnson & Johnson also gains an exclusive option to acquire Sail Biosciences for $2.85 billion. The deal puts J&J in the mix of pharmaceutical companies developing next-generation cell therapies for applications in autoimmune diseases. The post J&J Joins Immune Reset Race, Paying $785M to Partner on Sail Bio Cell Therapy appeared first on MedCity News.
Health and Health Care Experiences of Uninsured Immigrants
This brief provides data on health and health care experiences of uninsured immigrant adults based on a KFF survey of immigrant adults ages 18 and older conducted in partnership with The New York Times in Fall 2025. The data provide insight into how the projected coverage losses under the 2025 reconciliation law may impact health…
More Medications, Less Clarity: Strengthening Polypharmacy Support for CKD Patients
Interdisciplinary coordination between nephrologists, primary care providers, pharmacists, dieticians, and everyone who interacts with patients is essential to ensure patient education, improve adherence, and reduce medication errors. The post More Medications, Less Clarity: Strengthening Polypharmacy Support for CKD Patients appeared first on MedCity News.
The Code Gets You Paid — The Variant Gets You Treated
The between a code that satisfies a payer and the information a physician needs to treat a person, is what nearly every healthcare AI tool is racing past. As we push these systems toward precision medicine and genomics, that gap stops being an annoyance and becomes a patient safety issue. The post The Code Gets…
Moving Beyond Reactive Healthcare: 5 Traits of Successful Healthcare Organizations
[Sponsored] A new whitepaper by League highlights examples from collaborations with Baptist Health. The post Moving Beyond Reactive Healthcare: 5 Traits of Successful Healthcare Organizations appeared first on MedCity News.
KFF Health Tracking Poll: Mifepristone and the Midterms
Amid an ongoing FDA re-review of mifepristone, awareness of the safety and prevalence of the abortion pill remains limited. This KFF poll also finds that the voters who say abortion policy is an important issue for 2026 midterm candidates to discuss are disproportionately Democrats.
Medicaid Insurers’ Contracts on the Line in Tight Governor’s Race
One of America’s most competitive gubernatorial races could settle a heated argument over whether private insurance companies should run Medicaid. The race is in Iowa, whose Medicaid program has been plagued with controversy since 2016, when the state hired national insurance companies to manage billions of dollars’ worth of benefits. That shift was made by…
Abortion Drug Law in Louisiana Heightens Hemorrhage Risk for Pregnant Patients
Over the past decade, Louisiana hospitals began stocking specialized carts designed to treat hemorrhages, one of the most common pregnancy complications in the state. The plug-in cart can be wheeled from room to room and holds surgical tools and lifesaving medications to stem blood loss. A state law passed in 2024 forced hospitals to remove…
Doctronic Acquires Summer Health to Expand into Pediatric Primary Care
Doctronic acquired Summer Health to expand into pediatric care and strengthen its AI-powered primary care platform. The post Doctronic Acquires Summer Health to Expand into Pediatric Primary Care appeared first on MedCity News.
Processa Acquisition Lands Immunology Drug That Could Rival a New Novartis Product
With the merger, Processa’s new lead asset is a Vidya Therapeutics immunology drug that offers pipeline-in-a-product potential addressing a target that has clinical and regulatory validation from a recently approved Novartis drug. Vidya’s molecule is a next-generation drug that could have advantages over Novartis’s pill. The post Processa Acquisition Lands Immunology Drug That Could Rival…
